Phase IV trial of bupivacaine liposome injectable suspension (EXPAREL) in patients who underwent hip or knee arthroplasty

Trial Profile

Phase IV trial of bupivacaine liposome injectable suspension (EXPAREL) in patients who underwent hip or knee arthroplasty

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Bupivacaine (Primary) ; Bupivacaine; Ketorolac; Morphine
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Mar 2015 New trial record
    • 26 Mar 2015 Primary endpoint (Percent of VAS pain scores that were 0) has been met, according to Pacira Pharmaceuticals media release.
    • 26 Mar 2015 Primary endpoint (Visual Analog Scale (VAS) pain scores) has been met, according to Pacira Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top